linjc16/ctgov huggingface dataset:
Value of Transthoracic Ultrasonography (TTU) for Etiological Diagnosis of Acute Dyspnea: Cross Sectional Study

Study Overview
=================
Brief Summary
-----------------
Evaluating the capability and efficiency of transthoracic ultrasound in attempting to identify the etiology of acute dyspnea.

Detailed Description
-----------------
Acute dyspnea is a frequent challenge for physicians due to having multiple etiologies, leading to difficulty in establishing an accurate diagnosis. The presence of this symptom is already a predictor of increased mortality and a lot of investigations are required to differentiate between etiologies. Hence, prompt diagnosis is needed to streamline these patients' appropriate management and disposition from the ED. Transthoracic ultrasound has traditionally been used for the detection of pleural effusion and evaluation of the chest wall, but the indications have been expanded. The gold standard imaging technique for the majority of pulmonary disorders is high-resolution computed tomography (HRCT), but it has negatives which are: hazard of ionizing radiation high cost being nonportable

Official Title
-----------------
Value of Transthoracic Ultrasonography (TTU) for Etiological Diagnosis of Acute Dyspnea: Cross Sectional Study

Conditions
-----------------
Dyspnea

Intervention / Treatment
-----------------
* Device: Ultrasonography


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Clinical history of acute dyspnea Exclusion Criteria: Subcutaneous emphysema. Patients with more than 24 h interval between HRCT and TTU. Patients with poor-quality of TTU image.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Ultrasonography|Bedside thoracic ultrasound for patients complaining of acute dyspnea.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Differentiate between different etiologies of acute dyspnea | Analysis of ultrasound findings to differentiate between etiologies of acute dyspnea. | Baseline | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Detect value of transthoracic ultrasound (TTU) in comparison to CT chest. | Comparison between accuracy of TTU and CT | Baseline |
Ascorbic Acid and Ibuprofen in Infants With Hypoxic Ischemic Encephalopathy

Study Overview
=================
Brief Summary
-----------------
Oxygen radicals and inflammation are important causes for brain injury in neonates following perinatal asphyxia. Animal studies demonstrated potential benefits to the brain when using both of vitamin C and ibuprofen. The efficacy of these 2 drugs when combined in protecting the human brain has not been studied. We aimed in this study to test the hypothesis that a combination of anti-oxidants (vitamin C) and anti-inflammatory (ibuprofen) drugs can decrease the brain injury in perinatal asphyxia and improve outcomes when given to infants immediately after birth.

Official Title
-----------------
Ascorbic Acid Combined With Ibuprofen in Hypoxic Ischemic Encephalopathy: A Randomized Controlled Trial.

Conditions
-----------------
Hypoxic Ischemic Encephalopathy, Perinatal Asphyxia

Intervention / Treatment
-----------------
* Drug: Ascorbic acid (vitamin C)
* Drug: Ibuprofen
* Drug: Placebo


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Apgar score at 5 minutes < 6 Profound metabolic or mixed acidosis with pH < 7 in the initial blood gas Evidence of encephalopathy such as coma, seizures or hypotonia Evidence of multi-system compromise, in addition to encephalopathy Exclusion Criteria: Major congenital anomalies Early sepsis Gastrointestinal bleeding Thrombocytopenia

Ages Eligible for Study
-----------------
Maximum Age: 2 Hours

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Active Comparator: A<br>Infants will receive intravenous ascorbic acid and oral ibuprofen for 3 days | Drug: Ascorbic acid (vitamin C)<br>* IV, 100 mg/kg/day, every day, for 3 days<br>Drug: Ibuprofen<br>* PO, 10 mg/kg on day 1, 5 mg/kg/day on days 2 and 3 of life<br>|
| Placebo Comparator: B<br>Infants will receive equivalent amount of placebo | Drug: Placebo<br> <br> |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| DDST-II |  | 6 months | 
| Neurological Examination |  | 6 months | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Death |  | On Discharge | 
| Neurological Examination |  | On Discharge | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Interleukin 1-beta, Interleukin 6, Vitamin C, HIE, neonates
Level of Middle Cranial Fossa Dura in Patients With Cholesteatoma

Study Overview
=================
Brief Summary
-----------------
Cholesteatoma is a destructive lesion that progressively expands in the middle ear, mastoid or petrous bone and leads to destruction of the nearby structures. Erosion, which is caused by bone resorption of the ossicular chain and otic capsule, may cause hearing loss, vestibular dysfunction, facial paralysis and intracranial manifestations

Detailed Description
-----------------
Cholesteatoma has three Classical forms: (1) Congenital, primary or genuine cholesteatoma: occurs behind an intact tympanic membrane. Primary acquired cholesteatoma: looks like a limited diverticulum of the pars flaccida with little or no history of otorrhea. Secondary acquired cholesteatoma: develops with posterosuperior perforations in eardrum and expansion of the disease process into the antrum, mastoid, attic and middle ear. Granulation tissue, polyps and foul- smelling otorrhea are common findings in this type

Official Title
-----------------
Evaluation of the Level of Middle Cranial Fossa Dura in Patients With Cholesteatoma

Conditions
-----------------
Cholesteatoma, Middle Ear

Intervention / Treatment
-----------------
* Radiation: Multislice computed tomography temporal bone


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: All adults above the age of 18 presented to the Assiut university Clinic with cholesteatoma will be included in the study. Exclusion Criteria: Patients with previous mastoid surgery Patients with Craniofacial anomalies or cleft lip and palate Pediatric populations ≤ 18 years old Patients with congenital ear anomalies

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Patients with cholesteatoma<br>Patients with cholesteatoma in one ear that will compared with the other healthy one. | Radiation: Multislice computed tomography temporal bone<br>* Patients with cholesteatoma will undergo multislice computed tomography (MSCT) temporal bone images. Then The Tegmen level will be determined and compared with the other normal ear at the same patient<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of the Level of Middle Cranial Fossa Dura in Patients with Cholesteatoma by multislice computed tomography. | determination the level of tegmen in patients with attico-antral diseases by MSCT | One year |
Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients

Study Overview
=================
Brief Summary
-----------------
The study evaluates the safety and efficacy of Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients. The researchers hypothesize that additional Mesenchymal Stem Cell infusion can benefit the promising clinical islet transplantation through the following mechanisms: protection of islet from inflammatory damage, immunological modulation, engraftment promotion, thus decrease or eliminate the need of exogenous insulin and improve β-cell function.

Official Title
-----------------
Cotransplantation of Islet and Mesenchymal Stem Cell in Type 1 Diabetic Patients

Conditions
-----------------
Type 1 Diabetes Mellitus

Intervention / Treatment
-----------------
* Biological: cotransplantation of islet and mesenchymal stem cell


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male and female patients age 18 to 60 years of age Ability to provide written informed consent Manifest signs and symptoms that are severe enough to be incapacitating Patients with poor diabetes control (HbA1c > 7% but < 12%) Progressive diabetic complications Exclusion Criteria: age < 18 years or > 60 years diabetic history < 5 years BMI > 27 body weight > 80 kg exogenous insulin requirement > 1 unit/kg/day severe anemia (male < 8 g/dl, female < 7 g/dl) low white blood cell count (< 3000/dl) liver dysfunction Active infection including hepatitis B, hepatitis C, HIV, or TB panel reactive antibody > 20% Any medical condition that, in the opinion of the investigator, will interfere with the safe completion of the trial

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 60 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: 1<br>cotransplantation of islet and mesenchymal stem cell | Biological: cotransplantation of islet and mesenchymal stem cell<br>* islet of allograft and MSCs of autograft<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Exogenous insulin requirement |  | 5 | 
| Hemoglobin A1c |  | 5 | 
| Glucose and C-peptide levels |  | 5 | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| liver function |  | 5 | 
| kidney function |  | 5 | 
| Portal vein Ultrasound |  | 1 | 
| autoantibodies |  | 5 | 
| Complete Blood Count |  | 5 | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Islets of Langerhans Transplantation, Mesenchymal Stem Cells, Type 1 Diabetes Mellitus
SNaP Wound Care System Over Skin Cancer Excision Sites and Split Thickness Skin Grafts (STSGs)

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to evaluate the efficacy of the Spiracur SNaP® Wound Care System for the treatment of skin cancer excision sites and split thickness skin grafts (STSG). The secondary purpose will be to compare the prospective patients to retrospectively treated skin cancer excision sites and STSGs to further evaluate efficacy and safety.

Official Title
-----------------
Post-Market Clinical Evaluation of the Spiracur SNaP™ Wound Care System for Treatment of Skin Cancer Excision Sites and Split Thickness Skin Grafts

Conditions
-----------------
Skin Cancer Excision Site, Split Thickness Skin Graft, Skin Graft

Intervention / Treatment
-----------------
* Device: SNaP® Wound Care System


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Skin cancer excision site and/or STSG as the source of the wound on any part of the body including head and neck, torso, and extremities. Any other type of skin graft will also be eligible for inclusion into the study. Wound < 16 cm in greatest diameter Subject ≥ 18 years of age Female subjects of child-bearing potential must be willing to take a urine pregnancy test prior to starting study Subject is willing and able to sign informed consent Exclusion Criteria: Wound-related cellulitis Wound located in an area not amenable to forming an air-tight seal Subject has untreated osteomyelitis Subject is allergic to wound care products Wound has exposed blood vessels not suitable for negative pressure therapy Subject is actively participating in other clinical trials that conflict with current study Subject has fistulas Subject is pregnant

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| SNaP® Wound Care System<br> | Device: SNaP® Wound Care System<br>* Wound dressing applications using customized system. Dressing applications changes per manufacturer recommendation.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Wound Closure |  | 12 weeks |
Functional Outcome Anterior Cruciate Ligament Reconstruction

Study Overview
=================
Brief Summary
-----------------
The purpose of this study is to compare hop performance and jump landing strategy in soccer players with higher level sports activities after ACLR using either BPTB or STG and controls.

Detailed Description
-----------------
The choice of graft for anterior cruciate ligament reconstruction (ACLR) remains controversial. Despite the need for outcome studies comparing bone-patellar tendon-bone (BPTB) with semitendinosus and gracilis tendon (STG), few studies have evaluated functional outcomes. The objective of the current study was to compare hop performance and jump landing strategy in soccer players with higher level sports activities after ACLR using either BPTB or STG and controls.

Official Title
-----------------
Comparison of Functional Outcome Measures of Anterior Cruciate Ligament Reconstruction Using Either Patellar Tendon or Hamstring Tendon Grafts and Controls in Competitive Soccer Players: A Randomized Trial

Conditions
-----------------
Complications of Surgical Procedures or Medical Care

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: ACLR and controls. Exclusion Criteria: Musculoskeletal injuries

Ages Eligible for Study
-----------------
Minimum Age: 21 Years
Maximum Age: 30 Years

Sexes Eligible for Study
-----------------
Male

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| BPTB group<br>Bone-patellar tendon-bone | |
| STG group<br>Semitendinosus and gracilis tendon | |
| Control<br>Healthy | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Hop values for the both legs in Single, 6-m, Cross-over and Triple hops |  | Patients were followed up to 8 months post-surgery | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Landing and Take-off Ground Reaction Forces |  | Patients were followed up to 8 months post-surgery | 
| Strength of Quadriceps and Hamstrings |  | Patients were followed up to 8 months post-surgery | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Anterior Cruciate Ligament, Hamstrings versus patellar tendon, Hop test, Return to sports
Patient-reported Outcome Measures in Patient Underwent Total Hip and Knee Arthroplasty

Study Overview
=================
Brief Summary
-----------------
Registry of Galeazzi Orthopedic Institute: provides for the regular and systematic collection of all data (clinical and some PROMs) obtained from patients undergoing hip and knee arthroplasty to which questionnaires are proposed investigating the specific functional sphere of the joints undergoing surgery (Knee injuryOsteoarthritisOutcomeScore (KOOS-PS) and Hip injuryOsteoarthritisOutcomeScore (HOOS-PS) but also the sphere of general health (ShortForm health survey-12 (SF-12) and VisualAnalogueScale (VAS)) , in addition, of course, to the satisfaction rate.

Official Title
-----------------
Patient-Reported Outcome Measures in Patient Underwent Total Hip and Knee Arthroplasty in Galeazzi Orthopaedic Institute Milano

Conditions
-----------------
Hip Osteoarthritis, Knee Osteoarthritis, Prosthesis Survival

Intervention / Treatment
-----------------
* Procedure: arthroplasty


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: male and female age more than 18 patient underwent hip or knee arthroplasty Exclusion Criteria: age less than 18 comorbidity that can results in the difficulty to come back for the follow up

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| patient underwent hip and knee arthroplasty<br>Patients with hip and knee osteoarthritis underwent hip and knee arthroplasty included in inclusion criteria. | Procedure: arthroplasty<br>* patient with hip and knee osteoarthritis underwent hip and knee arthroplasty<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| outcome measurements | improve evaluation of hip and knee arthroplasty monitoring patient reported outcome measurements before and after surgery. | pre operative to 10 years |
Social Media Effect on Knowledge Dissemination During COVID-19 Virus Outbreak

Study Overview
=================
Brief Summary
-----------------
The recent COVID-19 outbreak is very challenging as data are distributed instantly on the data are very rapidly distributed through professional and non professional sources which may impact the management of the disease

Detailed Description
-----------------
The investigators are conducting a survey between the physicians to study the effect and practice of received knowledge disseminated through social media . the survey will be distributed through internet and data will be collected and analyzed

Official Title
-----------------
Impact of Social Media on Knowledge Dissemination Between Physicians During COVID-19 Virus Outbreak

Conditions
-----------------
COVID-19

Intervention / Treatment
-----------------
* Other: survey


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Medical Physicians in Middle East area Exclusion Criteria: none

Ages Eligible for Study
-----------------
Minimum Age: 25 Years
Maximum Age: 65 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: survey|online survey|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Number of physicians affected by social media measured by online survey designed to measure the influence of social media on medical practice | the survey will be send and received online and data will be analysed | one month | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Corona Virus, Social Media, Physician, Knowledge
Pharmacokinetics of Levofloxacin in Intensive Care Unit

Study Overview
=================
Brief Summary
-----------------
The aim of this study is 1. to describe levofloxacin pharmacokinetics in ICU patients suffering from pneumonia with taking into account physio-pathological parameters. 2. to verify clinical and bacteriological efficiency and to know if the peak/Minimum Inhibitory Concentration (MIC) ratio > 5 and Area Under Curve (AUC) /Minimum Inhibitory Concentration(MIC) ratio > 125. No therapeutic drug monitoring will be performed in this study.

Official Title
-----------------
Population Pharmacokinetics of Levofloxacin in Intensive Care Patients With Severe Community-acquired Pneumonia.

Conditions
-----------------
Intensive Care Unit Syndrome, Community-acquired Pneumonia

Intervention / Treatment
-----------------
* Drug: Levofloxacin


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: severe community-acquired pneumonia due to a strain sensible to levofloxacin Age > 18 years Informed consent SAPS II (simplified acute physiological score) > 20 Awaited duration of survival higher than 7 days Exclusion Criteria: Historic of allergy to levofloxacin Resistant strain to levofloxacin Pregnancy Contra-indications of levofloxacin use, renal failure

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Single Group Assignment
Masking: None (Open Label)


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Levofloxacin<br>Population having a community-acquired pneumonia of which the indication of the treatment is administration of Levofloxacin | Drug: Levofloxacin<br>* 8 blood sampling by patients between the 48th and 60th<br>* Other names: pharmacokinetic;|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Levofloxacin dosage regimen, time of administration and time of blood sampling, levofloxacin serum concentrations. |  | Levofloxacin concentration assessment at 8 different time points during 12h | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Efficiency (clinical,bacteriological, pharmacodynamic) | age, weight, height, sex, SAPS II, blood urea nitrogen (BUN), creatinine, mechanical ventilation, leukocytes, haemoglobin, procalcitonin, creatinine clearance, proteins, MIC of the strain. | 12 hours | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
pharmacokinetic study : open, prospective, monocentric